Harvard Apparatus Regenerative Technology Inc

For the period ended Sep 30, 2024. Filed Nov 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 13, 2024

HRGNStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share and per share data)

Three Months Ended · Nine Months Ended
	September 30,		September 30,
	2024	2023	2024	2023
Product revenue	$59	$40	$172	$40
Operating expenses:
Cost of sales	70	13	95	13
Research and development	557	339	2,039	2,414
Sales and marketing	143	143	455	198
General and administrative	1,148	1,169	3,944	4,577
Total operating expenses	1,918	1,664	6,533	7,202
Operating loss	(1,859)	(1,624)	(6,361)	(7,162)
Other (expense) income, net:
Other (expense) income, net	(1)	9	(27)	43
Net loss	(1,860)	(1,615)	(6,388)	(7,119)
Preferred stock dividends	—	—	—	(77)
Net loss attributable to common stockholders	$(1,860)	$(1,615)	$(6,388)	$(7,196)
Basic and diluted net loss per share attributable to common stockholders	$(0.12)	$(0.12)	$(0.44)	$(0.54)
Weighted average common shares outstanding, basic and diluted	15,017,591	13,882,060	14,410,034	13,297,391
Comprehensive loss:
Net loss	$(1,860)	$(1,615)	$(6,388)	$(7,119)
Foreign currency translation adjustments	(2)	—	(24)	—
Comprehensive loss	(1,862)	(1,615)	(6,412)	(7,119)
Less: Preferred stock dividends	—	—	—	(77)
Comprehensive loss attributable to common stockholders	$(1,862)	$(1,615)	$(6,412)	$(7,196)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.